PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
ROCKVILLE, Md., Feb 08, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 12th Annual BIO CEO & Investor Conference on February 8th, 2010 at 1:30 pm local time. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf=Astoria, New York. Dr. Singhvi will provide an overview of the company's business strategy, research and development progress and upcoming milestones. A link to the live audio only presentation can be accessed via the Company website at www.novavax.com under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

About BIO CEO & Investor Conference

Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. For more information, visit www.ceo.bio.org.

SOURCE Novavax, Inc.